BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
Tammy Hod, Aharon Ben‐David, Liraz Olmer, Noa Scott, Ronen Ghinea, Eytan Mor, Itzchak Levy, Victoria Indenbaum, Yaniv Lustig, Ehud Grossman, Galia Rahav
Abstract
85.9% of RTR develop NA to BNT162b2 third vaccine, found effective in both negative and positive responders prior to the vaccine. Antigenic re-exposure overcame the suppressive effect of MPA on antibody response in RTR.
Topics & Concepts
MedicineTiterAntibodyRenal functionImmunologyInternal medicineHumoral immunityMycophenolic acidPopulationNeutralizing antibodyTransplantationEnvironmental healthSARS-CoV-2 and COVID-19 ResearchRenal Transplantation Outcomes and TreatmentsHepatitis B Virus Studies